Chimeric Therapeutics Limited

CHIA:CHM Stock Report

Market Cap: AU$14.7m

Chimeric Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure2.4yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

CEO

Chimeric Therapeutics has no CEO, or we have no data on them.

Leadership Team

NamePositionTenureCompensationOwnership
Paul Hopper
Founder & Executive Chairman4.3yrsAU$250.00k11.01%
A$ 1.6m
Eliot Bourk
Chief Business Officer & Head of External Innovation2.4yrsAU$1.26mno data
Jason Litten
Chief Medical Officer1.9yrsAU$1.13mno data
Phillip Hains
CFO, Joint Company Secretary & Director3.7yrsno data1.2%
A$ 175.5k
Rebecca McQualter
Chief Operating Officerless than a yearno datano data
Kelly Thornburg
VP & Head of Quality2.3yrsno datano data
Nathan Jong
Company Secretary3.7yrsno datano data

2.4yrs

Average Tenure

63yo

Average Age

Experienced Management: CHM's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Hopper
Founder & Executive Chairman4.3yrsAU$250.00k11.01%
A$ 1.6m
Phillip Hains
CFO, Joint Company Secretary & Directorless than a yearno data1.2%
A$ 175.5k
Larry Couture
Member of Glioblastoma Expert Advisory Boardno datano datano data
Lesley Russell
Non-Executive Director3.8yrsAU$73.32k0.20%
A$ 29.6k
David Maloney
Member of Cellular Immunotherapy Scientific Advisory Board2.8yrsno datano data
Nader Sanai
Member of Glioblastoma Expert Advisory Boardno datano datano data
Yvonne Chen
Member of Glioblastoma Expert Advisory Board3.4yrsno datano data
Christine Brown
Chairman of Glioblastoma Expert Advisory Boardno datano datano data
Yi Lin
Member of Cellular Immunotherapy Scientific Advisory Board2.8yrsno datano data
Eric Smith
Member of Cellular Immunotherapy Scientific Advisory Board2.8yrsno datano data
Michael Bishop
Member of Cellular Immunotherapy Scientific Advisory Board2.8yrsno datano data
Benham Badie
Member of Glioblastoma Expert Advisory Boardno datano datano data

2.8yrs

Average Tenure

66yo

Average Age

Experienced Board: CHM's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.